YB-1 activating cascades as potential targets in KRAS-mutated tumors.
Strahlenther Onkol
; 199(12): 1110-1127, 2023 12.
Article
en En
| MEDLINE
| ID: mdl-37268766
ABSTRACT
Ybox binding protein1 (YB-1) is a multifunctional protein that is highly expressed in human solid tumors of various entities. Several cellular processes, e.g. cell cycle progression, cancer stemness and DNA damage signaling that are involved in the response to chemoradiotherapy (CRT) are tightly governed by YB1. KRAS gene with about 30% mutations in all cancers, is considered the most commonly mutated oncogene in human cancers. Accumulating evidence indicates that oncogenic KRAS mediates CRT resistance. AKT and p90 ribosomal S6 kinase are downstream of KRAS and are the major kinases that stimulate YB1 phosphorylation. Thus, there is a close link between the KRAS mutation status and YB1 activity. In this review paper, we highlight the importance of the KRAS/YB1 cascade in the response of KRAS-mutated solid tumors to CRT. Likewise, the opportunities to interfere with this pathway to improve CRT outcome are discussed in light of the current literature.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proteínas Proto-Oncogénicas p21(ras)
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Strahlenther Onkol
Asunto de la revista:
NEOPLASIAS
/
RADIOTERAPIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Alemania